MX2019003938A - Compuestos espirociclicos. - Google Patents

Compuestos espirociclicos.

Info

Publication number
MX2019003938A
MX2019003938A MX2019003938A MX2019003938A MX2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A
Authority
MX
Mexico
Prior art keywords
spirocyclic compounds
compounds
spirocyclic
ameliorating
treating
Prior art date
Application number
MX2019003938A
Other languages
English (en)
Inventor
Kahraman Mehmet
Qinhua Huang Peter
Duane Bunker Kevin
Original Assignee
Zeno Royalties & Milestones Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeno Royalties & Milestones Llc filed Critical Zeno Royalties & Milestones Llc
Publication of MX2019003938A publication Critical patent/MX2019003938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente descripción se describen compuestos espirocíclicos, junto con composiciones farmacéuticas y métodos para mejorar y/o tratar un cáncer descrito en la presente descripción con uno o más de los compuestos descritos en la presente descripción.
MX2019003938A 2016-10-05 2017-10-03 Compuestos espirociclicos. MX2019003938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404668P 2016-10-05 2016-10-05
PCT/US2017/054865 WO2018067512A1 (en) 2016-10-05 2017-10-03 Spirocyclic compounds

Publications (1)

Publication Number Publication Date
MX2019003938A true MX2019003938A (es) 2019-06-10

Family

ID=61831517

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003938A MX2019003938A (es) 2016-10-05 2017-10-03 Compuestos espirociclicos.

Country Status (13)

Country Link
US (2) US10934304B2 (es)
EP (1) EP3523306A4 (es)
JP (2) JP6949952B2 (es)
KR (1) KR20190075931A (es)
CN (1) CN109890827A (es)
AU (1) AU2017339890A1 (es)
BR (1) BR112019005305A2 (es)
CA (1) CA3037064A1 (es)
IL (1) IL265752A (es)
MX (1) MX2019003938A (es)
RU (1) RU2019107667A (es)
TW (1) TW201817732A (es)
WO (1) WO2018067512A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3822273B1 (en) 2012-06-13 2024-04-10 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
TWI649318B (zh) 2013-04-19 2019-02-01 英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
AU2016242940B2 (en) 2015-04-03 2020-11-05 Recurium Ip Holdings, Llc Spirocyclic compounds
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
AU2019262195A1 (en) 2018-05-04 2020-12-24 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
EP3846904B1 (en) 2018-09-07 2023-05-31 Merck Patent GmbH 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022004513A (es) 2019-10-14 2022-07-19 Incyte Corp Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN110922421B (zh) * 2019-12-17 2023-05-05 安徽英特美科技有限公司 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2799434B1 (en) * 2004-05-14 2017-08-02 Vertex Pharmaceuticals Incorporated Pyrrole compounds as inhibitors of ERK protein kinases and pharmaceutical compositions containing these compounds
BRPI0619823B8 (pt) * 2005-12-13 2021-05-25 Merck Sharp & Dohme compostos que são inibidores de erk
EP2086974B1 (en) 2006-11-17 2013-07-24 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
CN101772501A (zh) * 2007-06-18 2010-07-07 先灵公司 杂环化合物及其作为erk抑制剂的用途
WO2010027567A2 (en) 2008-07-23 2010-03-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
US9687550B2 (en) 2009-12-07 2017-06-27 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
EP2751118B1 (en) * 2011-08-29 2016-10-12 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
CN103130775B (zh) 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
US8987264B2 (en) * 2012-11-09 2015-03-24 Bristol-Myers Squibb Company 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C
JP6506248B2 (ja) 2013-03-14 2019-04-24 ゾーン・ロイヤリティズ・アンド・マイルストーンズ・エルエルシー 二環式鎮痛化合物
EP3237420B1 (en) 2014-12-22 2018-09-26 Eli Lilly and Company Erk inhibitors
CN105732636B (zh) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
AU2016242940B2 (en) * 2015-04-03 2020-11-05 Recurium Ip Holdings, Llc Spirocyclic compounds

Also Published As

Publication number Publication date
NZ751398A (en) 2021-03-26
RU2019107667A (ru) 2020-11-06
IL265752A (en) 2019-06-30
CA3037064A1 (en) 2018-04-12
WO2018067512A8 (en) 2018-11-01
RU2019107667A3 (es) 2021-01-27
JP2019534261A (ja) 2019-11-28
JP6949952B2 (ja) 2021-10-13
US20210115058A1 (en) 2021-04-22
US10934304B2 (en) 2021-03-02
WO2018067512A1 (en) 2018-04-12
BR112019005305A2 (pt) 2019-07-02
US20200207776A1 (en) 2020-07-02
CN109890827A (zh) 2019-06-14
AU2017339890A1 (en) 2019-04-11
EP3523306A1 (en) 2019-08-14
JP2021193138A (ja) 2021-12-23
KR20190075931A (ko) 2019-07-01
EP3523306A4 (en) 2020-05-06
TW201817732A (zh) 2018-05-16

Similar Documents

Publication Publication Date Title
MX2019003938A (es) Compuestos espirociclicos.
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX2021007773A (es) Compuestos inhibidores de egfr.
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
MA40404A (fr) Polythérapie pour traiter un paramyxovirus
MX2018003472A (es) Moduladores de la expresion de kras.
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MY187540A (en) Compounds active towards bromodomains
MX2017012553A (es) Compuestos espirociclicos.
MX2021009899A (es) Administracion y dosificacion de diaminofenotiazinas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX2017014436A (es) Compuestos biciclicos.
EP3413906A4 (en) COMBINATION COMPOSITIONS FOR CANCER TREATMENT, METHOD AND USES
WO2016130581A8 (en) Combination cancer therapy
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MX2019009199A (es) Composiciones y métodos para modular ppp2r1a.
WO2019028012A3 (en) METHODS OF USING PEMBROLIZUMAB AND TREBANANIB
MX2017008655A (es) Derivados de jasmonato y composiciones de los mismos.